BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Eculizumab: trial readouts and FDA decisions

1 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 2 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Alexion Pharmaceuticals, Inc., Nanjing Chia-tai Tianqing Pharmaceutical, Regeneron Pharmaceuticals. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-07 est.P3Alexion Pharmaceuticals, Inc.NCT06724809 Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSDNMOSD; Neuromyelitis Optica Spectrum Disordersactive not recruiting21

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P3Nanjing Chia-tai Tianqing PharmaceuticalNCT07177859 A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria PatientsParoxysmal Nocturnal Hemoglobinurianot yet recruiting78
2026-09-28P3Regeneron Pharmaceuticals REGNNCT05133531 A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNHParoxysmal Nocturnal Hemoglobinuriacompleted202

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.